General
Preferred name
BROMOPYRUVATE
Synonyms
3-Bromopyruvic acid ()
Bromopyruvic acid ()
Hexokinase II Inhibitor II, 3-BP ()
3-bromopyruvate ()
3-Bromopyruvic acid, 3-Bromopyruvate, Bromopyruvic acid, Hexokinase II Inhibitor II, 3-BP ()
P&D ID
PD038965
CAS
1113-59-3
206860-50-6
68-38-2
Tags
available
covalent binder
drug candidate
Drug indication
Discovery agent
Drug Status
investigational
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities[1][2][3].
PRICE
29
DESCRIPTION
This active molecular is a synthetic brominated derivative of pyruvic acid which is a hexokinase II inhibitor and an effective antitumor agent because it is a highly reactive alkylating agent. The acute toxicity study provided an LD50 of 191.7 mg/kg for 3-BrPA in vivo. In 2010, Preclinical trials in Cancer in USA (Intra-arterial) for bromopyruvate was approved. In 2013, US FDA approved IND application for bromopyruvate in Liver cancer .
(BOC Sciences Bioactive Compounds)
DESCRIPTION
3-Bromopyruvic acid is an alkylating agent and an antimetabolite of pyruvate that is metabolized through glutathione conjugation. It inhibits a metallo-beta-lactamase type 2. 3-Bromopyruvate inhibits cell growth and induces apoptosis.
(Enamine Bioactive Compounds)
DESCRIPTION
3-Bromopyruvic acid (Hexokinase II Inhibitor II, 3-BP) is a hexokinase II inhibitor with Ki of 2.4 mM for glycolysis/hexokinase inhibition. It is inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
19
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugMAP
Enamine Bioactive Compounds
Guide to Pharmacology
LINCS compound set
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
165.93
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
0.03
TPSA
54.37
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
0.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Apoptosis
Autophagy
Metabolism
Metabolic Enzyme/Protease
Member status
member
MOA
HK2 inhibitor
Target
Hexokinase
Carbohydrate Metabolism
hexokinase II
Solubility
DMSO, Ethyl Acetate, H2O : ≥ 32 mg/mL
Source data
